Intoxicación de equinos por Senecio pp en el noroeste argentino

La toxicidad de varias especies del género Senecio es bien conocida a nivel mundial. En Argentina se han descrito casos en bovinos pero los registros son escasos. En este trabajo se describen cuadros de seneciosis equina en dos predios rurales del noroeste argentino (Salta). Se mencionan los hallazgos clínicos y patológicos, caracterizados por fibrosis hepática, megalocitosis, hiperplasia biliar y colestasis. En individuos afectados se observó pérdida de peso, depresión, ataxia y dificultad para deambular. En las áreas de pastoreo se identificó la presencia de Senecio rudbeckiaefolius, S. madagascariensis y S. hieronymi. Se identificaron y cuantificaron alcaloides pirrolizidínicos en estas tres especies, mediante cromatografía gaseosa acoplada a espectrometría de masa. Se determinó la presencia de senecionina, integerrimina, usaramina, jacozina, jacobina, senecivernina, platyphyllina y neoplatyphyllina. Los resultados obtenidos confirman la intoxicación de equinos por Senecio en Argentina y ponen de manifiesto los primeros hallazgos de alcaloides pirrolizidínicos en tres especies de Senecio endémicas para el noroeste del país.The toxicity of several species of genus Senecio is well known worldwide. In Argentina there have been cases in cattle but records are scarce. In this paper equine seneciosis is described in two rural areas of argentinean northwest. Clinical and pathological findings characterized by hepatic fibrosis, megalocytosis, cholestasis and biliary hyperplasia, were recorded. In sick animals it was observed weight loss, depression, and ataxia. In grassing areas Senecio rudbeckiaefolius, Senecio madagascariensis and Senecio hieronymi were identified. Pyrrolizidine alkaloids were identified by gas chromatography coupled to mass spectrometry. Presence of senecionine, integerrimine, usaramine, jacozine, jacobine, senecivernine, platyphylline and neoplatyphylline was recorded. The results confirm Senecio poisoning in horses in Argentina and reveal the first finding of pyrrolizidine alkaloids in three endemic species of Senecio for Northwest ArgentinaEEA.SaltaFil: Micheloud, Juan Francisco. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Investigación Animal del Chaco Semiárido. Área de investigación en Salud Animal -EEA Salta; Argentina. Universidad Católica de Salta. Facultad de Ciencias Agrarias y Veterinarias; ArgentinaFil: Merep, P. Universidad Católica de Salta. Facultad de Ciencias Agrarias y Veterinarias; ArgentinaFil: Tomas, Rodrigo Hernán. Universidad Católica de Salta. Facultad de Ciencias Agrarias y Veterinarias; ArgentinaFil: Perotti, M. Universidad Católica de Salta. Facultad de Ciencias Agrarias y Veterinarias; ArgentinaFil: Schuff, C. Universidad Católica de Salta. Facultad de Ciencias Agrarias y Veterinarias; Argentin

Intoxicación de equinos por Senecio pp en el noroeste argentino

La toxicidad de varias especies del género Senecio es bien conocida a nivel mundial. En Argentina se han descrito casos en bovinos pero los registros son escasos. En este trabajo se describen cuadros de seneciosis equina en dos predios rurales del noroeste argentino (Salta). Se mencionan los hallazgos clínicos y patológicos, caracterizados por fibrosis hepática, megalocitosis, hiperplasia biliar y colestasis. En individuos afectados se observó pérdida de peso, depresión, ataxia y dificultad para deambular. En las áreas de pastoreo se identificó la presencia de Senecio rudbeckiaefolius, S. madagascariensis y S. hieronymi. Se identificaron y cuantificaron alcaloides pirrolizidínicos en estas tres especies, mediante cromatografía gaseosa acoplada a espectrometría de masa. Se determinó la presencia de senecionina, integerrimina, usaramina, jacozina, jacobina, senecivernina, platyphyllina y neoplatyphyllina. Los resultados obtenidos confirman la intoxicación de equinos por Senecio en Argentina y ponen de manifiesto los primeros hallazgos de alcaloides pirrolizidínicos en tres especies de Senecio endémicas para el noroeste del país

Hippocampal Volume Differences in Gulf War Veterans with Current Versus Lifetime Posttraumatic Stress Disorder Symptoms

Background: Decreased hippocampal volume is described in posttraumatic stress disorder (PTSD) and depression. However, it is not known whether it is a risk factor for the development of PTSD or a consequence of PTSD. We sought to determine the effects of PTSD and depressive symptoms on hippocampal volume. Methods: Clinical and magnetic resonance imaging data were collected in a cross sectional study of 244 GulfWarveterans. Measures included lifetime and current Clinician Administered PTSD Scale, Hamilton Depression Scale, Life Stressor Checklist, and Lifetime Drinking History. Magnetic resonance imaging data were acquired with a 1.5-T scanner and analyzed with automated and semiautomated image processing techniques. Results: Eighty-two veterans had lifetime PTSD, 44 had current PTSD, and 38 had current depression. In the linear regression analysis, current PTSD symptoms (standardized coefficient B= .25, p =.03) but neither lifetime PTSD symptoms nor current depression were associated with smaller hippocampal volume. Gender, age, history of early life trauma, education, lifetime and current alcohol use, current marijuana use, and treatment with antidepressants did not have independent effects. Participants with chronic PTSD had, on average, a smaller hippocampus compared with those with remitted PTSD. Conclusions: The finding that current but not lifetime PTSD symptom severity explains hippocampal size raises two possibilities: either a small hippocampus is a risk factor for lack of recovery from PTSD (trait) or PTSD effects on hippocampal volume are reversible once PTSD symptoms remit and the patient recovers (state)

Role of lipid apheresis in changing times

During the last decades, LDL-apheresis was established as an extracorporeal treatment option for patients with severe heterozygous or homozygous familial hypercholesterolemia (FH) that is resistant to conventional treatment strategies such as diet, drugs, and changes in lifestyle. Nearly half a century ago, the first LDL-apheresis treatment was performed by plasma exchange in a child with homozygous FH

Occipital Proton Magnetic Resonance Spectroscopy ((1)H-MRS) Reveals Normal Metabolite Concentrations in Retinal Visual Field Defects

BACKGROUND: Progressive visual field defects, such as age-related macular degeneration and glaucoma, prevent normal stimulation of visual cortex. We investigated whether in the case of visual field defects, concentrations of metabolites such as N-acetylaspartate (NAA), a marker for degenerative processes, are reduced in the occipital brain region. METHODOLOGY/PRINCIPAL FINDINGS: Participants known with glaucoma, age-related macular degeneration (the two leading causes of visual impairment in the developed world), and controls were examined by proton MR spectroscopic ((1)H-MRS) imaging. Absolute NAA, Creatine and Choline concentrations were derived from a single-voxel in the occipital region of each brain hemisphere. No significant differences in metabolites concentrations were found between the three groups. CONCLUSIONS/SIGNIFICANCE: We conclude that progressive retinal visual field defects do not affect metabolite concentration in visual brain areas suggesting that there is no ongoing occipital degeneration. We discuss the possibility that metabolite change is too slow to be detectable

Therapeutic apheresis in peripheral and retinal circulatory disorders

In microcirculation disorders, the therapeutic apheresis seems to have two different effects. The first, achieved after only a few sessions, is acute, consisting of drastic reduction of blood viscosity and obtained with the use of low-density lipoprotein (LDL) apheresis, rheopheresis, or fibrinogen apheresis. The second effect is long term, or chronic, and needs to be evaluated after a long course of treatment. The mechanisms underlying the chronic effect are still objects of debate and take into account the pleiotropic effects of apheresis. However, it is likely that the acute effect of apheresis mainly influences the functional components of the vascular damage, and so the derived rheological benefit might last only for a short period. The chronic effect, on the contrary, by acting on the morphological alterations of the vascular walls, requires the apheresis treatment to be prolonged for a longer period or even cycles of treatment to be programmed

Perfusion by Arterial Spin Labelling following Single Dose Tadalafil in Small Vessel Disease (PASTIS): study protocol for a randomized controlled trial

Background Cerebral small vessel disease is a common cause of vascular cognitive impairment in older people, with no licensed treatment. Cerebral blood flow is reduced in small vessel disease. Tadalafil is a widely prescribed phosphodiesterase-5 inhibitor that increases blood flow in other vascular territories. The aim of this trial is to test the hypothesis that tadalafil increases cerebral blood flow in older people with small vessel disease. Methods/design Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS) is a phase II randomised double-blind crossover trial. In two visits, 7-30 days apart, participants undergo arterial spin labelling to measure cerebral blood flow and a battery of cognitive tests, pre- and post-dosing with oral tadalafil (20 mg) or placebo. Sample size: 54 participants are required to detect a 15% increase in cerebral blood flow in subcortical white matter (p < 0.05, 90% power). Primary outcomes are cerebral blood flow in subcortical white matter and deep grey nuclei. Secondary outcomes are cortical grey matter cerebral blood flow and performance on cognitive tests (reaction time, information processing speed, digit span forwards and backwards, semantic fluency). Discussion Recruitment started on 4th September 2015 and 36 participants have completed to date (19th April 2017). No serious adverse events have occurred. All participants have been recruited from one centre, St George’s University Hospitals NHS Foundation Trust. Trial registration European Union Clinical Trials Register: EudraCT number 2015-001235-20. Registered on 13 May 2015

Proton spectroscopic imaging of brain metabolites in basal ganglia of healthy older adults

Object: We sought to measure brain metabolite levels in healthy older people. Materials and methods: Spectroscopic imaging at the level of the basal ganglia was applied in 40 participants aged 73–74 years. Levels of the metabolites N-acetyl aspartate (NAA), choline, and creatine were determined in "institutional units" (IU) corrected for T1 and T2 relaxation effects. Structural imaging enabled determination of grey matter (GM), white matter (WM), and cerebrospinal fluid content. ANOVA analysis was carried out for voxels satisfying quality criteria. Results: Creatine levels were greater in GM than WM (57 vs. 44 IU, p < 0.001), whereas choline and NAA levels were greater in WM than GM [13 vs. 10 IU (p < 0.001) and 76 versus 70 IU (p = 0.03), respectively]. The ratio of NAA/cre was greater in WM than GM (2.1 vs. 1.4, p = 0.001) as was that of cho/cre (0.32 vs. 0.16, p < 0.001). A low voxel yield was due to brain atrophy and the difficulties of shimming over an extended region of brain. Conclusion: This study addresses the current lack of information on brain metabolite levels in older adults. The normal features of ageing result in a substantial loss of reliable voxels and should be taken into account when planning studies. Improvements in shimming are also required before the methods can be applied more widely

Neuroimaging in Dementia

Dementia is a common illness with an incidence that is rising as the aged population increases. There are a number of neurodegenerative diseases that cause dementia, including Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, which is subdivided into the behavioral variant, the semantic variant, and nonfluent variant. Numerous other neurodegenerative illnesses have an associated dementia, including corticobasal degeneration, Creutzfeldt–Jakob disease, Huntington’s disease, progressive supranuclear palsy, multiple system atrophy, Parkinson’s disease dementia, and amyotrophic lateral sclerosis. Vascular dementia and AIDS dementia are secondary dementias. Diagnostic criteria have relied on a constellation of symptoms, but the definite diagnosis remains a pathologic one. As treatments become available and target specific molecular abnormalities, differentiating amongst the various primary dementias early on becomes essential. The role of imaging in dementia has traditionally been directed at ruling out treatable and reversible etiologies and not to use imaging to better understand the pathophysiology of the different dementias. Different brain imaging techniques allow the examination of the structure, biochemistry, metabolic state, and functional capacity of the brain. All of the major neurodegenerative disorders have relatively specific imaging findings that can be identified. New imaging techniques carry the hope of revolutionizing the diagnosis of neurodegenerative disease so as to obtain a complete molecular, structural, and metabolic characterization, which could be used to improve diagnosis and to stage each patient and follow disease progression and response to treatment. Structural and functional imaging modalities contribute to the diagnosis and understanding of the different dementias